Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 14, 2023

Efficacy and Safety of Switching From Dupilumab to Upadacitinib vs Continuous Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
J Am Acad Dermatol 2023 Sep 01;89(3)478-485, A Blauvelt, B Ladizinski, VH Prajapati, V Laquer, A Fischer, S Eisman, X Hu, T Wu, BM Calimlim, B Kaplan, Y Liu, HD Teixeira, J Liu, K Eyerich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading